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Abstract 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder causing dementia, a syndrome of 
gradual loss of cognitive function causing impairment in social and occupational functioning. This 
leads to substantial loss in quality of life and premature death for persons with the disease, 
associated suffering for their families and large costs to society. In parallel to the aging of the 
population the world prevalence is predicted to threefold within the next 40 years, creating a 
challenge for researchers and decision-makers to make better treatments available. Further, 
improved methods for economic evaluation in AD are needed to identify the optimal treatment 
strategies. The overall objective of this thesis is to explore the application of cost-utility analysis in 
AD and address key methodological challenges and data needs. 
 
In paper I, prediction functions for simulating disease progression and economic endpoints in a 
decision-analytic model were estimated. Three year follow-up data from the Swedish Alzheimer 
Treatment Study (SATS) on the natural course of AD of 435 patients commencing treatment with 
donepezil and their care setting and costs of care was analyzed. A simplified model in which 
cognition (representing the underlying course of disease) and the ability to perform activities of 
daily living (ADL) (representing patient care need) was assumed to predict the provision of care. 
According to the estimated statistical functions, cognition was found to be the key predictor of 
ADL-ability which itself was the main predictor of care setting and costs of care. 
 
In paper II, we used contingent valuation methods to elicit caregivers’ willingness-to-pay (WTP) 
for reductions in patient care need. In total, 517 caregivers of AD patients in four countries (Spain, 
Sweden, UK and US) were interviewed. The mean WTP for a one hour reduction per day was 
estimated at between £59 and £144 per month depending on country. The income of the 
caregiver was the only consistently significant determinant of WTP across all countries. 
 
In paper III, we assessed predictors of the costs of care of 1,222 AD patients in four countries 
(Spain, Sweden, UK and US), both residing in the community and in residential care settings. 
Cognition, ADL-ability, behavioural symptoms and costs of care (RUD-Lite) were assessed via a 
patient and caregiver interview. Cost estimates ranged between £1,000 to £5,000 per patient and 
month, increasing with disease severity and higher in residential care settings. ADL-ability was 
the most important predictor of costs but part of the variation was also explained by cognition and 
behavioural symptoms. 
 
In paper IV, the key components and drivers of costs of care in a clinical trial sample of 2,744 mild 
to moderate AD patients were identified. Costs were assessed with RUD-Lite at baseline and 
every 6 months over the 18 months trial. Informal care constituted 82-86 percent of total costs, 
whereas community care and patient accommodation constituted an equal share of 12-16 
percent. Informal care also had the strongest correlation with disease severity measures including 
cognition, ADL-ability, global function and behavioural symptoms. 
 
In conclusion, cognition, ADL-ability and behavioural symptoms are all important indicators of 
care need in AD and should be considered in economic modelling. Caregivers have a substantial 
willingness to pay for reductions in care need. Informal care is the key cost component in clinical 
trials in mild to moderate AD. Health utility estimates of AD patients are highly dependent on the 
methodology including choice of instrument, respondent and utility tariffs.  
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Abbreviations 
 
15D  15 domains  
AD  Alzheimer’s disease  
ADAS-cog  Alzheimer’s Disease Assessment Scale- cognitive subscale  
ADCS-ADL Alzheimer’s disease Cooperative Study- Activities of Daily Living 
inventory  
ADLs activities of daily living  
AHEAD  Assessment of Health Economics in Alzheimer’s Disease  
Behave-AD Behavioural Pathology in Alzheimer's Disease Rating Scale  
CADTH Canadian Agency for Drugs and Technologies  
CBA cost-benefit analysis  
CDR Clinical Dementia Rating scale  
CDR-SB CDR sum of boxes  
CEA  cost-effectiveness analysis  
CIBIC-plus  Clinician’s Interview-Based Impression of Change plus caregiver input  
CMA cost-minimization analysis  
CMAI  Cohen-Mansfield Agitation Inventory  
CRA  Caregiver Reaction Assessment  
CUA  cost-utility analysis  
CV contingent valuation  
DAD  Disability Assessment for Dementia scale  
DC dichotomous choice  
DES discrete event simulation  
DSM-IV Diagnostic and Statistical manual of Mental Disorders – Fourth Edition  
EGCg  Epigallocatechin-3-gallate  
EQ-5D EuroQoL – 5 domains 
FAST  Functional Assessment Staging  
FTC full time care  
HTA health technology assessment  
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HUI  Health Utility index  
IADL  Instrumental Activities of Daily Living scale  
ICD-10 International Statistical Classification of Diseases and Related Health 
Problems – tenth edition  
ICER  incremental cost-effectiveness ratio  
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NHS National Health Services  
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Stroke – Alzheimer’s Disease and Related Disorders  
NPI  Neuropsychiatric inventory  
PBAC ESC Economics Sub-Committee of the Pharmaceutical Benefits Advisory 
Committee  
PRO  patient reported outcomes  
PSMS  Physical Self-Maintenance Scale  
QALY  quality adjusted life year  
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RCT randomized controlled trial 
RUD Resource Utilization in Dementia  
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SG standard gamble  
SHTAC Southhampton Health Technology Assessments Centre  
SOS  National Board of Health and Welfare (Socialstyrelsen) 
TLV Dental and Pharmaceutical Benefits Agency (Tandvårds- och 
läkemedelsförmånsverket) 
TTO  time-trade-off  
WTA willingness-to-accept  
WTP  willingness-to-pay  
ZBI Zarit Burden Interview  
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1. Introduction 
1.1 Alzheimer’s disease 
1.1.1 Definition and diagnosis 
Alzheimer’s disease (AD) is a neurodegenerative disorder causing dementia, a syndrome first 
described by a German psychiatrist and neuropathologist, Alois Alzheimer, in 1906. These 
symptoms include the gradual loss of cognitive function causing impairment in social and 
occupational functioning (1). The cause of the disease is not known, although there are several 
hypotheses being explored including beta-amyloid accumulation and neurofibrillary tangles in the 
brain, leading to cell death and brain atrophy (2). 
 
A definite diagnosis of Alzheimer’s disease can only be established after autopsy (3). In practice, 
a clinical diagnosis is set after examination based on the Diagnostic and Statistical manual of 
Mental Disorders – Fourth Edition (DSM-IV), International Statistical Classification of Diseases 
and Related Health Problems – tenth edition (ICD-10), or National Institute of Neurological and 
Communicative Disorders and Stroke – Alzheimer’s Disease and Related Disorders (NINCDS-
ADRDA) criteria (4-6). The DSM-IV criteria are as follows: 
 
A. The development of multiple cognitive deficits manifested by both 
(1) memory impairment (impaired ability to learn new information or to recall previously 
learned information.) 
(2) one (or more) of the following cognitive disturbances: 
(a) aphasia (language disturbance) 
(b) apraxia ( impaired ability to carry out motor activities despite intact motor function) 
(c) agnosia (failure to recognize or identify objects despite intact sensory function) 
(d) disturbance in executive functioning (i.e., planning, organizing, sequencing, 
abstracting) 
B. The cognitive deficits in Criteria A1 and A2 each cause significant impairment in social or 
occupational functioning and represent a significant decline from a previous level of 
functioning. 
C. The course is characterized by gradual onset and continuing cognitive decline. 
D. The cognitive deficits in Criteria A1 and A2 are not due to any of the following: 
(1) other central nervous system conditions that cause progressive deficits in memory and 
cognition (e.g., cerebrovascular disease, Parkinson’s disease, Huntington’s disease, 
subdural hematoma, normal-pressure hydrocephalus, brain tumor) 
(2) systemic conditions that are known to cause dementia (e.g., hypothyroidism, vitamin 
B12 or folic acid deficiency, niacin deficiency, hypercalcemia, neurosyphilis, HIV 
infection) 
(3) substance-induced conditions 
E. The deficits do not occur exclusively during the course of a delirium. 
F. The disturbance is not better accounted for by another Axis I disorder (e.g., Major 
Depressive Disorder, Schizophrenia). 
 
DSM-IV is mostly used in research while the Swedish system for medical records is built around 
ICD-10. There are new versions currently being developed for both systems: DSM-V (expected in 
May 2013) (7) and ICD-11 (8). The proposed revision for DSM-V includes removing the term 
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dementia and instead sort the dementias under a new category called Major Neurocognitive 
disorder (9). 
 
Alzheimer’s disease is the most common cause of dementia, accounting for 50 to 70 percent of all 
dementia cases (1). Other common causes include vascular dementia and dementia with Lewy 
bodies. Mixed dementia is also common, primarily cases with both Alzheimer pathology and 
vascular lesions (10). 
1.1.2 Burden of dementia 
The worldwide prevalence of dementia was estimated at 34.4 million in 2009 (11) of which 
potentially 17-24 million have Alzheimer’s disease (based on the 50-70 percent estimate). 
Alzheimer’s Association estimates the US prevalence of Alzheimer’s disease at 5.3 million (12). 
The world prevalence will increase over the next decades as a consequence of the aging 
population and the demographic transition in developing countries. A recent report predicted that 
66 million people worldwide would be affected by dementia in 2030 and 115 million in 2050 (13). 
 
Dementia affects society on several levels. Patients suffer from loss of function and quality of life 
as the disease progresses and ultimately premature death at the terminal stage. Their family and 
friends suffer from losing their loved ones but also from burden perceived from caring for the 
patient (14). Finally, the societal cost of dementia makes it one of the most costly disorders of our 
time. The worldwide societal costs were estimated at 422 billion US dollar in 2009 out of which a 
third ($142 billion) was costs of informal care from family and friends (11). In parallel to the aging 
of the population and increase in the prevalence of dementia, the economic burden of dementia is 
projected to increase rapidly over the next decades (13). 
1.1.3 Staging of disease 
The progressive nature of AD can be divided into three stages: mild, moderate and severe. The 
border between the three is diffuse and there are no strict criteria for progressing into a more 
severe stage. In general, in the mild stage, patients have impaired intellectual, social and 
occupational abilities, but are still capable of taking care of themselves. In the moderate stage, 
their cognitive impairment gets worse and they get dependent on care from others to carry out 
their activities of daily living (ADLs). In the severe stage they are dependent on constant care 
from others (15). The figure below is a reproduction from the literature describing the cognitive 
decline over time and its implications on patient dependence and care need (16, 17). 
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Figure 1 Staging the course of Alzheimer’s disease (16, 17) 
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There are several instruments for assessing the severity of Alzheimer’s disease. Many of them 
are used both to stage the disease and to serve as primary endpoints in clinical trials testing 
efficacy of novel treatments. 
1.1.3.1 Cognitive function 
The Mini-Mental State Examination (MMSE) (18), is a screening instrument for the assessment of 
cognitive impairment, and also a common tool for severity staging. It gives a score between 0 and 
30 points, which can be stratified into mild (21 - 26), moderate (10 - 20), moderately severe (10 – 
14) and severe (0 - 9) cognitive impairment (19). These cut-offs are not consistent across studies 
and alternative ranges have been reported in the literature (20). The MMSE is widely spread both 
in clinical practise and in research studies including randomized controlled trials (21). Another, 
and more comprehensive instrument for assessing cognitive function, is the Alzheimer’s Disease 
Assessment Scale- cognitive subscale (ADAS-cog) ranging from 0 to 70 points with increasing 
impairment (22). 
1.1.3.2 Function or ADL-ability 
Function or ability to carry out ADLs, offer an alternative method for staging the disease course 
reflecting the independence of the patient and consequently their need for care. There are many 
instruments available for assessing function, most of them being administered to the primary 
caregiver of the patient as an informant. Some of the more common instruments include: 
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 The Physical Self-Maintenance Scale (PSMS) (23) includes 6 basic ADL domains 
(toileting, feeding, dressing, grooming, physical ambulation and bathing) forming a total 
score between 0 and 6 indicating in how many domains the patient is independent.  
 The Instrumental Activities of Daily Living scale (IADL) (23) consists of eight instrumental 
ADL domains (using the telephone, shopping, preparing food, housekeeping, laundering, 
transportation, handling medications, and handling finances) forming a total score 
between 0 and 8 indicating in how many domains the patient is independent. 
 The Disability Assessment for Dementia scale (DAD) (24) measures both basic and 
instrumental ADLs and gives a score ranging between 0 and 100 with increasing 
independence. The score reflects the proportion of tasks that the patient can perform. 
 The Alzheimer’s disease Cooperative Study- Activities of Daily Living inventory (ADCS-
ADL) (25) assesses both basic and instrumental ADLs. The administration takes about 20 
minutes and gives a score from 0 to 78 with increasing dependency. 
 Functional Assessment Staging (FAST) (26) characterizes the functional course of AD in 7 
steps with increasing disability. 
1.1.3.3 Global assessment 
Global clinical assessments, such as the Clinical Dementia Rating scale (CDR) (27), are also 
common and usually combine both cognitive and functional domains to stage the disease. These 
measures are more dependent on the rater as their aim is to assess their clinical impression of 
the severity of the patient (21).  
1.1.4 Outcomes in clinical trials 
Cognition, functional ability (or ADL-ability) and global assessments are usually primary endpoints 
in clinical trial. The global assessment is then more focused at the change of symptoms over time 
rather than staging the disease at each point in time. To this end, there are specific instruments 
for clinical trials including Clinician’s Interview-Based Impression of Change plus caregiver input 
(CIBIC-plus) (28) and CDR sum of boxes (CDR-SB) (27, 29, 30). 
 
Behavioural symptoms are not commonly used to stage the course of the disease but they are an 
important part of AD and an important endpoint in clinical trials. The most widely used instrument 
for their assessment is the Neuropsychiatric inventory (NPI) (31) which assesses the presence, 
frequency and severity of behavioural symptoms. It is also available in a shorter version (32). 
Other instruments include the Behavioural Pathology in Alzheimer's Disease Rating Scale 
(Behave-AD) (33) which assesses behavioural symptoms via an interview with the caregiver as 
well as direct observation of the patient, and the Cohen-Mansfield Agitation Inventory (CMAI) 
(34). 
1.1.5 Patient care 
As the disease progresses, patients become increasingly dependent on others. At first they 
usually need help with instrumental ADLs such as cleaning, shopping and cooking food. In later 
stages they also lose the ability to carry out basic ADLs such as eating, toileting and dressing. A 
family member or friend (a so called informal caregiver) commonly assists the patient with such 
tasks in early stages of the disease. In many health care systems there are also community 
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services available (e.g. home helpers, home-delivered food and day care centres) to alleviate the 
burden on the informal caregiver. As patients deteriorate into worse stages and the demand for 
care increases, many patients move into residential care settings with varying levels of nursing 
assistance available (35). 
 
The National Board of Health and Welfare (SOS) is a Swedish governmental agency with one of 
its purposes to promote high quality health care provision in Sweden. They issued national 
guidelines on dementia care in 2010, with specific recommendations for optimizing the care of 
demented elderly. First, the establishment of a correct diagnosis is expected to result in improved 
care and a thorough diagnostic assessment should therefore be conducted whenever dementia is 
suspected. Second, the care should be organized with the needs of the individual patient at focus 
and carried out by multi-professional teams which should get adequate training in dementia care. 
Third, all patients should be re-assessed and their care re-evaluated at least annually. Fourth, the 
available pharmacological treatments should be offered to patients when indicated (including 
cholinesterase inhibitors and memantine). Fifth, dementia specific day care and specialized living 
should be offered to dementia patients. Sixth, support should be offered to the family of the 
patient education, respite care and psychosocial support (36). 
1.1.6 Pharmaceuticals 
1.1.6.1 Currently available treatments 
There is no cure available for Alzheimer’s disease, but there are four symptomatic drug therapies 
currently indicated for AD. Three of them are cholinesterase inhibitors for the treatment of mild to 
moderate AD: donepezil (Aricept®), rivastigmine (Exelon®) and galantamine (Reminyl®). All 
three compounds have shown efficacy on cognitive function and global endpoints in short-term (3-
6 months) randomized controlled trial (RCT) in mild to moderate AD. Function, i.e. ability to carry 
out ADLs, has been assessed in placebo-controlled trials with duration up to 60 weeks with 
significant efficacy favouring active treatment while behaviour has only been assessed in 
donepezil and galantamine with some evidence of efficacy (37). Donepezil is also indicated for 
severe dementia in the US but not in Europe (38). The fourth symptomatic treatment, memantine 
(Ebixa®), is a NMDA receptor antagonist for the treatment of moderately severe to severe AD. 
Memantine have shown significant efficacy on cognition, function and global endpoints in 24 
weeks randomized trials (39). 
1.1.6.2 Current therapeutic targets 
Memantine was the latest drug to receive approval for treatment of AD in 2002 in Europe, and 
2003 in the US. Since then, many candidate compounds have failed due to lack of efficacy and/or 
unacceptable side effects. However, there are still many potentially capable drugs being explored 
and a handful of them have reached the third clinical phase and are currently tested in pivotal 
registration trials. These include bapinuzemab and solanezumab, two passive immunotherapies 
targeted at clearing A from the brain that is believed to play an important role in the 
pathogenesis of AD. Another is Epigallocatechin-3-gallate (EGCg) which may inhibit toxic A-
aggregation. Other drugs with different modes of action are currently tested in smaller clinical 
samples in phase 2. These include active immunotherapies, drugs that prevent the production of 
A (i.e. -secretase activators and -secretase and -secretase inhibitors), drugs that target tau 
proteins (a parallel hypothesis next to A accumulation potentially causing the disease) and new 
cholinergic drugs. See Mangialasche for a recent review (2). 
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1.2 Methods for economic evaluation 
1.2.1 Definition 
Drummond et al. define economic evaluation as “the comparison of two or more alternative 
courses of action in terms of both their costs and consequences” (40). It is always comparative as 
the benefit of a potential intervention can only be measured if compared to an alternative, even if 
the alternative is doing nothing. The costs may constitute not only the costs of a specific 
intervention, but also the potential cost offsets in other parts of the health care system which are 
caused by the intervention. For instance, if a vaccination programme results in a lower care need 
in the future, this implies cost savings on coming budgets. Similarly, the outcomes of an 
intervention vary, may affect more people than the patient and can be measured with different 
endpoints. 
1.2.2 Types of economic evaluations 
There are different types of economic evaluations, differing mainly in the way the outcomes are 
measured. The following sections give an overview and comprehensive reviews are available 
elsewhere (40, 41). 
1.2.2.1 Cost-minimization analysis 
Whenever two interventions give the same outcome we would prefer the least costly of them. This 
is the principle of cost-minimization analysis (CMA). In practise, outcomes are rarely exactly the 
same which justifies some trade-off between a better outcome and a lower cost. 
1.2.2.2 Cost-effectiveness analysis 
In cost-effectiveness analysis (CEA) we allow two interventions to differ not only in their costs but 
also in their outcomes, or so called effectiveness. The effectiveness needs to be measured 
quantitatively, e.g. number of months of survival. We may then calculate the additional cost (the 
cost difference between the two interventions) of the additional effectiveness (in our example 
additional survival). This ratio is called the incremental cost-effectiveness ratio (ICER) defined as 
the difference in costs divided by the difference in effectiveness. 
 
Our preferred intervention then depends on what our willingness-to-pay (WTP) is for the 
additional effectiveness. If we can identify a threshold for our WTP (e.g. £35,000 for every 
additional year of life) we may introduce a decision rule to invest in all interventions that result in a 
cost per every added year of life below or equal to this threshold. 
1.2.2.3 Cost-utility analysis 
A cost-utility analysis (CUA) is a special case of CEA in which all outcomes are translated into a 
common measure reflecting the individual’s relative preference for the different outcomes. This 
measure is often referred to as utility, also (incorrectly) in cases when the theoretical properties of 
utilities are not fulfilled. The expected utility theory rests on a set of assumptions first described by 
von Neumann-Morgenstern (42). In order for a preference measure to be a utility in its strict 
meaning, it needs to take the individual’s risk attitude into account. An individual may for instance 
prefer a certain outcome to a gamble between a better and a worse outcome, even if the 
expected value of the certain outcome and the gamble are equal. For this so called risk averse 
individual, the utility is therefore higher for the certain outcome than for the gamble. The opposite 
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is called risk seeking, i.e. a preference for risky gambles although the expected value of a certain 
outcome is equal. In many applications, preferences are measured when there is no uncertainty 
of the outcome in which case we should rather speak of the perceived value of an outcome than 
the perceived utility of the same.  
 
In practise, the quality adjusted life year (QALY) is a commonly used preference outcome in 
economic evaluation. It is based on the assumption that people would be willing to trade between 
the length and quality of life, where each possible health state is associated with a quality of life 
value which can be depicted on an index scale. This scale is cardinal, meaning that there is an 
order of preference (i.e. the higher the scale value the more preferred is the outcome) and that 
the scale intervals have a meaning (i.e. an increment of 0.1 is equally preferred irrespective of 
location on the scale). The scale is usually anchored between 1 (perfect health) and 0 (dead). The 
QALY is then defined as the equivalent of one year of perfect health (e.g. 2 years in a health state 
with a scale value of 0.5 equals 1 QALY).  
 
There are several methods for eliciting the quality of life of a certain health state. One of the more 
common methods is the time-trade-off (TTO) in which an individual is asked to choose between 
two scenarios: health state A for x years followed by death or perfect health for a fixed number of 
years followed by death. The number of years x is increased/decreased until a cut-off is reached. 
The ratio between the cut-off x and the fixed number of years is then assumed to be the quality of 
life or utility of health state A. Another common method which takes the respondent’s risk attitude 
into account is the standard gamble (SG). The respondent is now asked to choose between 
health state A for t years, or a gamble with the probability p of perfect health for t years and the 
probability (1-p) of immediate death. The probability p is increased/decreased until a cut-off is 
reached and the probability p is then assumed to be the utility of health state A. 
 
The TTO and SG are both direct methods to assess utilities in the study sample. However, the 
direct assessment is complex and time consuming. Indirect measures such as the EuroQoL – 5 
domains (EQ-5D) (43) are therefore commonly used. The EQ-5D is a generic (i.e. applicable 
across multiple diseases) health indexing system developed for an easy and rapid estimation of 
the health utility of different health states. It contains five domains (mobility, self-care, usual 
activity, pain/discomfort and anxiety/depression) with three different levels, together forming 243 
possible health states. Scoring algorithms or tariffs estimated from external sources are thereafter 
used to link each health state to a certain utility. One such tariff is available from a UK sample of 
about 3,000 individuals who elicited the utility of the EQ-5D health states using TTO methods 
(44). The utility derived with EQ-5D is thus determined by the preferences of an external 
population scoring the health state reported by the patient. 
 
Other generic instruments to assess health utilities of different health states include the Health 
Utility index (HUI) (45) and the 15 domains (15D) (46). HUI Mark 2 includes seven domains with 
four to five levels within each domain. A later version, HUI Mark 3, includes eight domains with 
five to six levels within each domain. The 15D instrument assesses fifteen domains, each rated 
on a 5-point scale. 
 
The use of cost-utility analysis (and QALYs in specific) is recommended for reimbursement 
submissions in many countries because they enable comparison of interventions across different 
disease area, irrespective of their outcome. 
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1.2.2.4 Cost-benefit analysis 
In a cost-benefit analysis (CBA), all outcomes are translated into monetary values. The net benefit 
of an intervention is calculated by subtracting its incremental cost from the incremental monetary 
value of its outcomes. The decision maker should then invest in all interventions with a net benefit 
above zero. 
1.2.3 Costing 
1.2.3.1 Cost studies 
Cost of illness studies do not by themselves offer any evidence of the value of a treatment. They 
are primarily used to explore the magnitude of the burden of a disease and draw the attention of 
policy makers and sponsors to particular needs for investment and research. However, data from 
cost of illness studies can be useful in economic models when combined with other sources on 
disease progression and treatment efficacy. Cost data should then be available for each of the 
relevant patient subgroups, i.e. defined by severity of symptoms, care setting and care need etc. 
This data can be collected with a bottom-up approach in which individual patients are assessed 
and estimates of the mean costs per patient are derived from a sample of patients with similar 
characteristics (the alternative top-down approach, in which aggregated data from e.g. national 
accounts are broken down to different subcategories, are generally not useful in this context).  
 
Bottom-up cost studies can also be used to identify the important components of costs (i.e. how 
costs are distributed across different types of resources) and cost drivers (i.e. what determines 
the level of costs). This data is useful prior to the decision on what resources to capture in a study 
to ascertain that data on the most relevant costs are collected.  
 
What costs to include in economic evaluation depends on the perspective of the analysis. In 
practice, the governmental agencies controlling or providing guidance on reimbursement 
decisions, set the standards for the economic evaluation of health care interventions in each 
country. In Sweden, the Dental and Pharmaceutical Benefits Agency (TLV), recommends a 
societal perspective, in which the costs of all stakeholders are considered (47). In England, the 
National Institute for Health and Clinical Excellence (NICE), requires a third party payer 
perspective which only takes into account the costs of the public health care system (and 
disregards e.g. private and indirect costs) (48). 
1.2.3.2 Value of informal care 
In economic evaluation, each resource should be valued at their opportunity cost which is defined 
as the value of their best alternative use on the market. Due to market imperfections, this may not 
be exactly reflected by the market price of the resource, but market prices are generally perceived 
to be close enough unless there are certain circumstances that merit adjustments (40).  
 
Informal care (i.e. unpaid care, usually provided by a family member or friend) is not available on 
the market and the opportunity cost is therefore difficult to assess. There have been many 
alternative approaches proposed on how to estimate the value of informal care including the 
human capital, friction cost and replacement cost methods (49). The human capital method 
assumes that production is foregone while the informal caregiver provides care to the patient, and 
the opportunity cost should therefore be equal to this production loss. The friction cost method 
assumes that someone else covers the production loss due to the absence of the informal 
caregiver and the opportunity cost is therefore equal to the friction in which the responsibility and 
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knowledge is transferred to another person. The replacement cost method considers the value of 
informal care to be equal to the value of an alternative carer (e.g. a formal carer available on the 
market). 
 
None of the above methods takes the caregiver’s preferences into account and is therefore 
ignorant of the potential value or burden associated with the care giving as perceived by the 
caregiver. The revealed preference approach observes true transactions within the society which 
reveals peoples’ preferences. The value of a reduction in waiting time may for instance be equal 
to the additional price people are willing to pay for moving ahead in the waiting line, which may be 
observable within the market. However, there are limitations in what preferences can be elicited 
this way as many scenarios do not occur in everyday life. 
1.2.3.3 Contingent valuation methods 
An alternative to revealed preference studies is contingent valuation (CV) methods (also known 
as the stated preference approach), which explores how people respond to hypothetical scenarios 
which are presented to them (49). 
 
There are several ways of eliciting value in contingent valuation and the methods do indeed have 
impact on the results. The answers from the respondents are sensitive to what, when and by 
whom questions are asked and how they are formulated. Respondents may be influenced by the 
amount of material presented to them and too little information may lead to misinterpretation of 
questions (50). The payment vehicle (i.e. whether paid out of pocket, via a tax increase or an 
insurance premium) may affect the value expressed by the respondent. Another factor is what 
expectations the respondent has on the future, e.g. do they know that they will have use of the 
offered good or service or not. The reliability of the response may depend on the respondent’s 
relationship with the interviewer and whether the respondent perceives certain incentives to 
respond in specific ways. For instance, if the patient of a caregiver is present during the interview, 
the caregiver’s responses on questions relating to caregiver burden may be affected. 
 
Willingness-to-pay (WTP) and willingness-to-accept (WTA) are two sides of the same coin but 
they commonly give different results. The price people are willing to pay to get something has 
been shown to be lower than the price people who have the same are willing to accept to give it 
away. One of the proposed causes of this difference is that WTP is limited by the available budget 
whereas WTA is not. 
 
Four of the most frequently used elicitation methods in CV studies are: open-ended questions, 
bidding games, payment cards and discrete indicators. In open ended questions, the respondents 
are asked to state their maximum WTP which is simple, fast and straight forward but can also be 
demanding for the respondent. Bidding games may be easier as respondents are given an offer 
and then asked to either accept or reject it. Depending on the answer the offer is increased or 
decreased until a threshold (of maximum WTP) is reached. Payment cards provide a range of 
amounts in a single question from which the respondent is asked to select their maximum 
willingness-to-pay. The bidding game and payment cards are associated with biases related to 
the starting point (in the bidding game) (51) and range of values (payment card) (52). These 
biases can be avoided by the discrete indicator method (also referred to as dichotomous choice 
(DC) or take-it-or-leave-it-offers) in which the respondent is given one offer to accept or reject but 
without any bidding game following their response. The one offer is varied across respondents to 
explore how the proportion of accepts depends on the price, from which the mean WTP among all 
respondents can be estimated. This method is popular for its similarity to market transactions but 
may need a larger sample since we do not obtain the WTP from each respondent (53). Another 
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problem with the discrete indicator method is that respondents may want to express their 
appreciation of the good or service and accept an offer although the price is too high (in all three 
other methods, the respondent is given the opportunity to set a low price). Overestimation due to 
this so called yea-saying can be avoided by asking the respondent to state how certain they were 
of their response and only consider certain responses as accepts (54). 
1.2.4 Patient-level data analysis 
There are several sources of evidence in the economic evaluation of a new therapy. The 
randomized controlled trials (RCT), which are conducted prior to the registration of a new drug, 
offer a first opportunity to estimate the cost-effectiveness in a trial setting (so called within-trial 
cost-effectiveness) (55). These estimates have high internal validity (they are valid within the 
setting studied) but usually low external validity (the results are not necessarily applicable to the 
clinical practise setting). They are primarily designed to test efficacy and safety and therefore not 
optimal for cost-effectiveness analysis. The most important reasons for a low external validity are 
that patients are selected (e.g. less morbid than the overall patient population to alleviate risk of 
attrition), their care patterns are probably affected by the protocol (may have had no or additional 
visits if not enrolled into the study), and they are only followed over short periods of time (55). 
Most ongoing trials today include resource utilization as a secondary endpoint in their pivotal 
registration trials (56).   
 
After registration, there may be opportunities to conduct experimental studies to test the cost-
effectiveness in patients in a more realistic setting (so called phase 4 studies). However, such 
studies would need to recruit many patients and have long duration in order to capture effects on 
currently available endpoints considered of relevance to patients (e.g. institutionalization). This 
may not be feasible due to practical and ethical constraints in withholding potentially beneficial 
treatment for patients in the comparator arm of such a trial (56). 
 
In comparison, registries and observational studies in clinical practise may have higher external 
validity to the general populations but the internal validity is lower because they lack a control 
group which is needed to identify a causal effect of the treatment (57). Instead, they can be used 
to study the natural course of the disease, treatment patterns and costs in a real life setting. They 
can also be used to follow time trends in the uptake of a new intervention and to explore whether 
there has been any change in health outcomes which may be linked to such intervention. 
Registries can also be used to validate findings from clinical trial and economic models, to 
evaluate treatment programmes and potentially inform risk sharing schemes by showing whether 
pre-specified outcomes have been reached.  
1.2.5 Decision-analytic modeling 
Drummond et al. suggests a number of rationales for the use of decision-analytic models (40). 
First, they allow for indirect comparison between all contingent comparators which may be 
unfeasible and costly in an experimental trial setting. Second, they allow for the combination of 
evidence e.g. linking intermediate endpoints assessed in trial with final endpoints that are more 
relevant to patients. Third, they allow for evaluating long-term outcomes, which would again be 
unfeasible, costly and delay decisions if assessed in experimental trials. Further, models allow for 
sensitivity analyses which are primarily performed to test the assumptions in the model but are 
also useful for exploring what uncertainties are important for the outcomes. 
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There are different types of modeling techniques and there is some debate on the optimal 
technique (58). Irrespective of the choice of modeling technique, input data is needed on disease 
progression over time and costs and outcomes related to specific health states or events. 
1.2.5.1 Markov cohort simulation 
One of the standard models in economic evaluation is the Markov cohort simulation. For this 
model, a set of health states are defined each associated with a certain cost and outcome and 
time is divided into preset time frames: so called cycles. At baseline, the patient cohort is 
distributed over the health states according to the characteristics of the studied population. 
Transition probabilities, defined as the probability of a patient moving from one state to another 
within a given cycle are derived from epidemiological data. At each cycle, the cohort of patients is 
redistributed over the states according to the transition probabilities. The costs and outcomes of 
spending a cycle in each state are multiplied with the proportion of patients in each state. As the 
model is run, cycles are added one by one and patients are moving from state to state, the costs 
and outcomes of the patient cohort accumulate. The model can be run with several arms with 
different assumed treatment effects (e.g. by altering the transition probabilities). Thereby, the 
accumulated costs and outcomes of different interventions can be compared, and their 
incremental cost-effectiveness calculated. 
 
The figure below shows a state transition diagram of an exemplary Markov model. The arrows 
show the possible transitions. Patients are allowed to stay in three of the states more than one 
cycle, as is indicated by the bowed arrows. In the event state you are only spending one cycle at 
a time. In this example, either you enter the disabled state or you die. The dead state is a 
terminate state which is indicated by the absence of arrows to any other state. The double arrow 
between the event and disabled states indicates that there are possible transitions back and forth 
between these states. However, ones you have experienced an event you will never go back to 
the well state.  
 
Figure 2 Markov state transition diagram 
   
Well   
  
Event   
  
  
Disabled      
  
Dead   
 
 
A special feature of the Markov cohort simulation is that future events are independent of what 
happened in previous cycles, also referred to as the Markov property. This since we cannot 
separate between patients who are in the same state. Thus, the transition probabilities depend on 
which state you are presently in, but not in which states you previously have been. This can be 
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overcome by adding more states, e.g. by adding a state for secondary events in the figure above 
and only let patients be in the primary event state once. 
 
Another method to overcome the Markov property is to use another method for evaluating the 
Markov model. In the Markov Chain Monte Carlo simulation (MCMC), one subject is followed at a 
time which enables considering the events of previous cycles as the subject moves through the 
model. The simulation with a single subject is done a very large number of times, every time with 
new inputs, i.e. transition probabilities and cost etcetera. This will result in a random variation in 
individual outcomes, sometimes referred to as the first-order uncertainty. This cannot be done in a 
Markov cohort simulation since we study a cohort, consisting of subjects with various histories. 
1.2.5.2 Alternative modeling approaches 
Discrete event simulation (DES) offers an alternative approach to simulate the disease course 
(59). Instead of evaluating the model over fixed cycles, the DES estimates the time until next 
event for individual patients. This can be based on statistical functions in which the time to one 
event is dependent on patient characteristics and the occurrence of other events. Whenever an 
event has occurred, the model recalibrates and estimates the time to the next event. Costs and 
outcomes can then be linked to the events and accumulated over time, similar to the Markov 
cohort simulation. 
 
A similar approach, the survival model, also estimates the time to the next event but multiple 
events have a hierarchical order (e.g. moving to the next severity levels). The resulting survival 
curves can be combined with data on costs and outcomes on each level to derive long-term 
outcomes (60). 
1.2.6 Health policy application 
The need for economic evaluation in health care has become evident as decision makers are 
faced with multiple alternatives for investments of their limited health care budgets. Simply 
selecting all interventions with a benefit for the patient until the resources have finished is not 
optimal, because alternative strategies may help more people with higher needs resulting in a 
healthier population overall.  
 
The development of Health Technology Assessment (HTA) and economic evaluation as an 
instrument to inform decisions in health care started in the early 90-ies. The pioneering institutions 
were the Canadian Agency for Drugs and Technologies (CADTH) (61) and the Economics Sub-
Committee of the Pharmaceutical Benefits Advisory Committee (PBAC ESC) in Australia (62), 
which were both established in 1993. Today, HTA is a centrepiece in health care decision making 
in most developed countries. In England, the National Institute for Health and Clinical Excellence 
(NICE), develops guidance on the use of pharmaceuticals and procedures to the National Health 
Services (NHS). NICE demands drug manufacturers to submit a thorough economic evaluation of 
drugs to be prescribed in England (48). In practise, the rationale for a negative opinion can be an 
ICER that is too high which results in the drug not getting reimbursed by public funds and 
therefore not being prescribed to English patients. In Sweden, the Dental and Pharmaceutical 
Benefits Agency (TLV), both evaluates the evidence of new drugs (as submitted by the drug 
manufacturer) and makes a decision whether it should get reimbursed by public funds. Their 
decision is based on three principles: 1) cost-effectiveness (cost should appear reasonable from 
the medical, humanitarian and economic aspects), 2) the principle of need and solidarity (those 
with the greatest medical needs should be prioritized) and 3) the principle of human value 
(respect for equal dignity of all human beings) (63).  
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1.3 Economic evaluation in Alzheimer’s disease 
1.3.1 Economic evaluation of AD drugs 
The economic evaluation of the cholinesterase inhibitors and memantine has played a significant 
role in determining their availability to patients in many countries. Patient access to cholinesterase 
inhibitor and memantine treatment varies across countries. Even though they have been 
approved by regulatory agencies in most countries, many HTAs are sceptic of their benefits 
(especially in relation to the drug costs) (56). The clinical trials only show modest effects on short-
term surrogate endpoints and the value for patients is uncertain. The drug manufacturers have 
presented evidence of reductions in informal care and institutionalization rates from treatment, 
causing cost offsets which are comparable to the cost of the drug (64-68). However, this data is 
largely built on assumptions of long-term effects and has not convinced all HTAs. For instance, 
NICE recommends only to prescribe the cholinesterase inhibitors in moderate AD (excluding mild 
AD) and not to prescribe memantine at all. The recommendations were based on estimates of 
poor cost-effectiveness in these indications (19). 
1.3.2 Modeling in Alzheimer’s disease 
In the first models in AD, which were developed to estimate the cost-effectiveness of the 
cholinesterase inhibitors, the progression of the disease was represented by cognitive function 
alone. In a typical model, three disease severity states (mild/moderate/severe) were defined by 
MMSE scores and transition probabilities between the states over time indicated the rate of 
deterioration in cognitive function. A symptomatic treatment effect was applied by imposing a 
reduction in the probability of moving to a worse state for treated patients (data usually derived 
from RCT). As each state differed in terms of costs of care and health outcomes, the model 
simulation estimated the accumulated cost offsets from treatment and the difference in health 
outcomes between the treatment and comparator arms (69, 70).  
 
A subsequent model, the Assessment of Health Economics in Alzheimer’s Disease (AHEAD) 
model, utilized the patient’s need for full time care (FTC) as surrogate endpoint to estimate cost-
effectiveness (59). Prediction functions to simulate the proportion of patients in FTC over time 
were derived from a US sample of 236 patients (71). The cognitive function of the patient 
(measured by the modified mini-mental state examination, mMMS) was the main predictor 
together with presence of extrapyramidal symptoms, presence of psychotic symptoms, young age 
at disease onset and duration of illness. The AHEAD model was later modified by the 
Southhampton Health Technology Assessments Centre (SHTAC) as part of the HTA of all 
dementia treatments commissioned by NICE (72). SHTAC named a number of limitations of the 
AHEAD model, including the crude representation of the disease process with only two states 
(FTC and non-FTC) plus death, prediction functions being derived from a small sample of patients 
with high attrition over time, and statistical uncertainties in the prediction functions. They 
concluded that the AHEAD model could be used for illustrative purposes, in absence of any better 
model. In their recommendations for further research, SHTAC called for studies on other markers 
than cognitive function for the prediction of disease progression (especially ADL and functional 
outcomes). 
1.3.3 Cost of AD 
There are several studies available on the cost of AD patients in various countries and settings 
(20). They differ in their objectives, scope and methods which is ultimately reflected in large 
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differences in their results. Cost estimates for Europe range between €6,000 and €64,000 per 
patient and year, depending on country, study sample and methodology (20). We know from 
previous studies that costs increase with the severity of the disease, irrespective of what 
symptoms are at focus. Some evidence suggests that ADL-ability is the main cost driver (73-80), 
other that behavioural symptoms affects costs (81, 82), and potentially that these two domains 
together mediate the variance observed in costs by level of cognitive function (i.e. the cognitive 
function of a patient may not explain any additional variance in costs when controlling for ADL-
ability and behavioural symptoms) (83). We also know that the costs of residential care settings 
(e.g. care homes, group livings or nursing homes) constitute a significant part of the life-time costs 
of an AD patient (82, 84). Studies showing delays in the need of such facilities also show 
important reductions in overall costs (84, 85). 
1.3.3.1 Assessment of resource utilization in AD 
There are several instruments for the assessment of resource utilization in dementia. The most 
widely spread is probably the Resource Utilization in Dementia (RUD) instrument which captures 
the health care resource utilization of the patient and their informal caregiver (86). RUD is also 
available in a short version (RUD Lite) which assesses the most important resources from a 
costing perspective, constituting 95% of the costs of the complete instrument (87). RUD is 
administered via an interview with the informal caregiver of the patient.  
 
RUD includes an assessment of the time spent on informal care. The care provision is divided 
into three tasks: basic ADLs, instrumental ADLs and supervision. The caregiver is asked to 
consider a typical day during the past month when providing care to the patient and state how 
many hours they spent on basic ADLs. Thereafter, the caregiver is asked how many such days 
there were during the past month. The caregiver is then asked to consider the same (hours on a 
typical care day and number of such care days) for instrumental ADLs and finally supervision. 
With this data we may then calculate the mean care provision during the past month. We may 
especially be interested in the time spent on active care and then exclude the time spent on 
supervision. 
 
The recall time is set to one month because caregivers are expected to be able to remember how 
much time they have spent on care during this time frame. Longer recall periods reduces the 
reliability of the responses. 
 
These methods have been validated both in a sample of patients in group living cared for by 
professional staff (88) and in another sample of community dwelling patients with an informal 
caregiver (89). Still, many caregivers perceive they are caring for the patient around the clock 
which may lead to overestimations of the time spent on care. This can be avoided by asking the 
caregiver how much time they spend asleep on average and deduct this time from the available 
number of hours per day. A common method is also to cap the reported time at 18 hours per day 
to reflect the expected maximum (68). 
1.3.4 Outcomes in AD 
The primary endpoints to assess the efficacy of new drugs in Alzheimer’s disease RCTs are set 
by regulators such as European Medicines Agency (90) and Food and Drug Administration (FDA) 
in the US (91). In Europe, the primary endpoints should include cognition and function (ADL-
ability) (90). 
  
23 
The relevance of these efficacy endpoints to patients is uncertain and therefore less appropriate 
for HTA and reimbursement decisions. Guidelines on the economic evaluation of drugs from 
NICE and TLV suggests cost-utility analysis and the use of QALYs for measuring outcomes (47, 
48). Because none of the existing pharmacological therapies have shown any effect on mortality, 
the main focus has been to show a benefit on the patient’s quality of life from treatment. NICE 
recommends the use of the generic EQ-5D instrument to assess the health utility weights in cost-
effectiveness analysis (48).  
 
There are also disease specific quality of life instruments available, most notably the Quality of 
life- Alzheimer’s disease (QoL-AD) (92) and DEMQOL (93, 94). QoL-AD contains 13 items with 
four levels per item and assesses the quality of life of the patient both by patient self-report and 
the caregiver as a proxy. DEMQOL is an interviewer-administered questionnaire which is 
specifically designed for use in people with probable dementia and has been validated in mild and 
moderate dementia, but is not suitable in severe dementia. DEMQOL-proxy is the 31 item version 
of the test and is designed for those caring of people with dementia. 
 
Due to the cognitive impairment of patients in severe stages of AD, they commonly have 
difficulties in completing patient reported outcomes (PRO) such as the quality of life instruments. 
Instead, the caregiver has commonly been asked to complete the quality of life assessments as a 
proxy for the patient. This was done by Neumann et al. who showed that patient health utilities, 
assessed with HUI, decreased with increasing severity (95). Jönsson et al. let both patients and 
their caregivers complete the EQ-5D instrument to assess the health utility of the patient. The 
estimated utilities using the caregiver proxy-reports were higher than those based on the patient 
reports across all severities, and also more sensitive to the severity of cognitive symptoms as 
assessed by MMSE (96). Karlawish et al. further explored the relationships between quality of life, 
assessed with EQ-5D and HUI-II and reported by both the patient themselves and the caregiver 
as proxy, and other outcomes related to the health and perceptions of the patient and the 
caregiver (97, 98). They questioned the validity of patient-reported quality of life estimates based 
on limitations in their correlation with cognitive and functional impairment (as reported by the 
caregiver). Patients were also found to have limited awareness of their cognitive and functional 
impairment. In a second paper (98), they also found limitations in caregiver reported quality of life 
of the patient including the absence of a significant correlation between the caregiver ratings and 
patient subjective domains on self-reported quality of life. They also found that caregiver 
perceived burden had an impact on their ratings of patient quality of life.  
 
Caregiver burden is another key outcome in Alzheimer’s disease. It can be assessed objectively 
by measuring the time spend on care tasks (86) or subjectively by asking caregivers about their 
perceived burden from caring for the patient. There are multiple instruments for this assessment 
including the Zarit Burden Interview (ZBI) (99) and the Caregiver Reaction Assessment (CRA) 
(100). Caregiver burden may also have an effect on the quality of life of the caregiver (14). 
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2. Thesis objectives 
 
The overall objective of this research is to explore the application of cost-utility analysis in 
Alzheimer’s disease and address key methodological challenges and data needs. The four 
papers have the following specific objectives. 
 
 Estimate prediction functions of Alzheimer’s disease progression for economic evaluation 
(paper I) 
 Estimate the value of informal care from a caregiver perspective (paper II) 
 Assess predictors of costs of care of patients with varying severity of AD in a usual care 
setting (paper III) 
 Identify the key components and drivers of costs in clinical trial (paper IV) 
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3. Summary of papers 
3.1 Economic analysis of data from the Swedish Alzheimer Treatment Study 
(paper I) 
3.1.1 Objective 
We utilized data from a treatment registry, Swedish Alzheimer Treatment Study (SATS), which 
primary objective was to evaluate the long-term effects of cholinesterase inhibitor treatment in 
patients with AD in a routine clinical setting (101). The objective of paper I was to derive 
prediction functions for simulating disease progression and economic endpoints in a decision-
analytic model. 
3.1.2 Data 
The first SATS cohort of 435 patients commenced treatment with donepezil and was followed 
semi-annually for up to three years. Data were captured via a patient interview collecting 
demographics, disease history, cognitive function, ADL-ability, global change and resource 
utilization. Cognitive function was assessed with MMSE and ADAS-cog, ADL-ability with PSMS 
and IADL and global change with CIBIC. Resource utilization was not captured with any standard 
instrument but included community care services (home help, home-delivered meals and day 
care) and dates of moves into an institutionalized care setting. 
 
SATS also included other cohorts of patients commencing rivastigmine and galantamine 
treatment. The design and procedures in these treatment arms were identical to the donepezil 
arm, but only the donepezil cohort was considered in paper 1 because the data collection in the 
other arms had not finalized at the time of analysis.  
 
We retrieved additional data on inpatient care resource utilization from the Swedish national 
patient register. Still, the resource data in the SATS study combined with what could be collected 
from Swedish registers does not give a complete picture on the resource use of the patients. Key 
components that were missing include informal care and outpatient visits. The main contribution 
from SATS was instead its unique data on the long-term progression of Alzheimer’s disease 
progression, represented both by the gradual loss of cognitive function and ADL-ability of 
patients. 
3.1.3 Prediction functions 
We created an economic model based on the data available. We let the cognitive function of 
patients represent the underlying course of the disease which resulted in loss of ADL-ability over 
time. As patients lost their ability to care for themselves we assumed this would trigger a care 
need and consequently utilization of health care resources. Depending on the care setting this 
would give rise to various levels of costs of care. The model is depicted in the figure below. 
26 
Figure 3 Structure of economic model. The progression of dementia (represented by cognitive 
function) is assumed to cause loss of ADL-ability which determines the patient’s need for care. The 
care need consequently translates into care provision and costs to society. 
Cognitive 
severity ADL-ability Care setting Costs of care 
Dementia Care need Provision of care 
The level of costs of care was very different for patients residing in an institutionalized care setting 
compared to those living in the community, and many patients in the community had no costs at 
all. Therefore, we predicted costs in three steps. First, we estimated a prediction function for 
patients moving into an institution using survival analysis. Second, we estimated the probability of 
a community dwelling patient having a non-zero cost using logistic regression. Third, we predicted 
the actual cost of patients with a non-zero cost. This method aimed to be able to replicate the 
skewed distribution of costs as commonly seen in Alzheimer’s disease, where many patients have 
zero costs, some have very high costs with small variation across subjects and over time (those 
residing in institutions), and the rest have costs in between with higher variance across subjects 
and over time.  
3.1.4 Cross-validation 
The model was evaluated based on its ability to replicate the SATS study data. We did not want 
to validate it by replicating the same data as used for prediction (in-sample validation) so instead 
we sampled half of the study data for prediction and tried to replicate the other half combining the 
prediction functions with the baseline input from the replication half of the data. In order to explore 
the impact of what observations were included in each of the halves, we created an iterative 
process which was performed 1,000 times, each time randomly drawing a new half of the study 
sample for prediction to replicate the remaining half. 
3.1.5 Results 
The cross-validation process showed a good fit of our model predictions on observed data of 
costs over three years: the confidence intervals were overlapping for every 6 months period from 
baseline. 
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Figure 4 Comparison of predicted and observed mean 6-months costs of care and 90 % confidence 
intervals (SEK) over time. The 5th, 50th and 95th percentiles of 1,000 mean estimates are shown. (10 
SEK ~ 1 Euro) 
 
 
The mean cognitive decline per 6 months was ranging between 1.6 and 4.0 ADAS-cog points, 
increasing with disease severity. ADAS-cog was a significant predictor of ADL-ability (both PSMS 
and IADL) together with demographics (age and gender) and time from baseline. ADL-abilities (as 
measured by both PSMS and IADL) were (together with age and gender) significant predictors of 
the risk for institutionalization and non-zero costs. ADL-ability also correlated with the level of non-
zero costs. 
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3.2 Willingness-to-pay for reductions in care need (paper II) 
3.2.1 Objective 
The objective of the study for paper II was to explore the value of informal care using contingent 
valuation methods. We wanted to learn how much caregivers would be willing to pay for 
reductions in the care need of the patient. 
3.2.2 Data 
The study was performed in four countries (Spain, Sweden, the UK and the US) and 517 
caregivers were interviewed in total. Demographics of both the patient and the caregiver and the 
score of the latest MMSE assessment of the patient were captured. In a face-to-face interview 
with a study nurse, the caregiver was asked about their time spent on informal care, perceived 
caregiver burden (CRA), and the ADL-ability (DAD) and presence of behavioural symptoms (NPI) 
of the patient. The caregiver was then asked questions on their willingness-to-pay for a 
hypothetical scenario where the care need of the patient was reduced. 
3.2.3 Contingent valuation questions 
The caregivers were given two scenarios: first a reduction in the time needed to care for their 
patient by one hour per day and then a total elimination of the care need of their patient. For each 
scenario the reduction was offered at a price which they were asked to either accept or reject. If 
they accepted the price, they were asked about the certainty in their response. Then a bidding 
game followed to elicit their maximum WTP for the scenario. This way we combined the discrete 
indicator (also called dichotomous choice) and bidding game methods for separate analyses. The 
initial price differed across five groups to which the caregivers were randomly allocated.  
3.2.4 Analysis 
Maximum WTP for each scenario and country was estimated using three different methods. In a 
first parametric approach, a logistic regression function was estimated with the discrete indicator 
response as the dependent variable and the price as the independent variable. The resulting 
function was assumed to represent the demand curve for the scenario and the mean WTP was 
then given by the area under this curve. In the second approach, a non-parametric method was 
used to calculate the area under the curve by interpolation between the observed proportions of 
accepts by price on the x-axis. We assumed all caregivers would be accepting the reduction in 
care need at zero cost and none would be willing-to-pay more than the maximum bid (see figure 
below). 
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Figure 5 Demand curve for reduction in care need 
 
 
 
The third approach simply calculated the mean of the maximum WTP amounts resulting from the 
bidding game. 
3.2.5 Results 
A majority of caregivers were willing to pay to reduce the care need of their patient. Estimates 
ranged between £59 and £144 per month for a reduction of one hour per day, depending on 
country (estimated by parametric dichotomous choice methods). These estimates are comparable 
to the price of symptomatic treatment achieving this reduction in care need. Estimates were about 
four times higher for the total elimination of care need.  
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Figure 6 Mean WTP estimates for 1 h reduction in patient care need by country and estimation 
method (95% bootstrapped CI) 
Mean Willingness-to-pay for 1-hour reduction in patient care need (95% CI)
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There was substantial variation in WTP within and between countries and they were highest in the 
US and lowest in Sweden. In the US, caregivers were more often the child of the patient whereas 
most Swedish caregivers were a spouse living with the patient. Spouses may recognize the care 
giving as their rightful responsibility whereas a child may be more prone to opting out if the 
opportunity comes. It is also reasonable to believe that there are cultural differences between 
countries resulting in different attitudes towards care giving and thus different willingness to pay 
for alternatives. In all countries, the stated willingness-to-pay increased with higher income. 
Otherwise there were no consistent predictors of WTP across all countries.  
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3.3 Cost of Alzheimer’s disease patients in clinical practise (paper III) 
3.3.1 Objective 
The objectives of the study for paper III were to assess what measures of disease severity are the 
most important predictors of costs of care and whether these differed across countries. We also 
collected data on the burden perceived by caregivers and their quality of life which were the main 
topics of another publication from this study (14).  
3.3.2 Data 
The study was performed in four countries (Spain, Sweden, the UK and the US) and 1,222 
patients and their caregivers were interviewed in total. Patients with a clinical diagnosis of 
Alzheimer’s disease were recruited from memory clinics and primary care centres. An 
assessment of the cognitive function of the patient was conducted with MMSE. An interview with 
the caregiver assessed the ADL-ability (DAD), presence of behavioural symptoms (NPI) and 
resource utilization (RUD-Lite) of the patient. The caregiver also responded to a questionnaire 
including their perceived caregiver burden (ZBI) and their own and their patient’s health utility 
(15D). 
3.3.3 Disease severity stratification 
We wanted to explore how costs and outcomes differed between patients across the whole 
spectrum of the disease. Therefore we defined six subgroups according to the disease severity of 
the patient (MMSE states: mild, moderate or severe) and their care setting (community or 
residential care setting). The study centres were encouraged to recruit patients into each of the 
subgroups and at the end of the study we closed the recruitment into large subgroups and asked 
the centres to focus on those with few patients. As this probably led to an over-recruitment into 
subgroups with relatively few patients, the overall sample should not be considered representative 
to the Alzheimer population as a whole. 
3.3.4 Estimating costs of care 
The resource utilization of the patient during the last 30 days prior to the study visit was collected 
via an interview with the caregiver using the RUD-Lite questionnaire. The informal care section 
included a question on how much time the caregiver spent asleep per night. Their time awake 
was assumed to set the limit of the maximum number hours they could care for the patient. The 
resource use was multiplied by a price vector collected for each country. The human capital 
method was used to value informal care. The time spent on care instead of working was valued at 
the average gross wage in each country and the remaining time spent on ADL care was valued at 
35 percent of the average gross wage. Supervision was assumed to have a value equal to zero. 
3.3.5 Results 
Mean costs of care ranged between £1,000 per patient and month for mild patients living in the 
community to £5,000 for patients living in residential care settings. Cost estimates varied across 
countries and increased with the severity of disease for patients in community dwellings. 
 
ADL-ability was the most important predictor of costs of care of community dwelling patients. A 
one-point decrease on the DAD scale resulted in a 1.4 to 2 percent increase in costs on average, 
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or a 45 percent increase from a standard deviation decrease on DAD. NPI-severity and MMSE 
also had a significant impact on costs but the effects sizes were smaller. The caregiver-reported 
health utility of the patient decreased with increasing severity of symptoms and was lower for 
patients in residential care settings. Mean estimates ranged between 0.52 (severe patients in 
residential care setting) and 0.76 (mild community dwelling patients). 
 
Table 1. Determinants of costs of care in community dwellings   
  
Percentage change in 
costs of care from 
index change in 
determinant  
Percentage change in 
costs of care from 
standard deviation 
change in determinant
DAD -1.4% *** -45%
MMSE 0.9% * 6%
NPI-severity 1.0% * 8%
Sweden 74% ***  
UK ns   
US 28%   
Interaction DAD*Sweden -0.6% *  
Interaction DAD*UK ns   
Interaction DAD*US ns    
* p <0.05, ** p<0.01, *** p<0.001    
ns = non-significant (p>0.1)     
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3.4 Cost of Alzheimer’s disease patients in a clinical trial setting (paper IV) 
3.4.1 Objective 
We utilized the baseline and placebo follow-up data from two registration trials of a putative 
disease modifier in Alzheimer’s disease. The purposes of our study (the objectives of paper IV) 
were to identify the key resource items in a RCT setting and assess how they are correlated with 
one another and with measures of disease severity. 
3.4.2 Data 
Data were retrieved from two multicenter, randomized, double-blind, placebo-controlled, parallel-
group twin trials of Xaliproden and their double-blind 24 month extension trials. In total, 2,744 
patients with a diagnosis of probable Alzheimer’s disease according to the NINCDS-ADRDA 
criteria, MMSE score between 16 and 26 (inclusive), previously untreated of on stable AD 
treatment since 6 months, residing in the community and having a caregiver spending at least 4 
hours times 4 days or 2 hours times 7 days per week were enrolled and used in analysis. 
Baseline data from both trial arms and follow-up data from the placebo arm were used in the 
analysis. Thereby, none of the observations in the data set were from a patient currently receiving 
the study drug. The data collected and used in our analysis included demographics, disease 
severity (CDR-SB), cognitive function (MMSE and ADAS-cog), ADL-ability (ADCS-ADL), 
behavioural symptoms (NPI) and resource utilization (RUD Lite).  
3.4.3 Estimating costs of care 
RUD-Lite was administered with a recall time of one month for all resources except 
hospitalizations which had a recall time of one month for baseline and 6 months for the follow-up 
visits. The time the caregivers reported spending at caring for their patient was capped at 18 
hours per day to avoid overestimation of informal care provision. A common price vector from the 
UK was used for all patients as no comparisons across patients from different countries were 
made.  
3.4.4 Analysis 
Correlations between the measures of disease severity and resource utilization and costs at 
baseline were estimated. As resource utilization was collected retrospectively, the resource 
utilization and costs during the month preceding the actual assessments of disease severity were 
considered in the analysis. 
3.4.5 Results 
Informal care was the dominating cost in the randomized clinical trial, constituting over 80 percent 
of total costs. Informal care also had the strongest correlation, of all cost items, with the disease 
severity of patients. ADL-ability (measured with ADCS-ADL) was the strongest predictor of costs 
of care, of all disease severity measures. 
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Figure 7 Mean annual costs of care (£) by ADL-ability groups; all baseline observations with 
complete RUD and ADL-ability data (n=2,727), (1 GBP = 1.17 EUR = 1.43 USD) 
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4. Discussion 
4.1 Role of cost-utility analysis in Alzheimer’s disease 
What is the role of cost-utility analysis in Alzheimer’s disease in future economic evaluation? The 
difficulties in assessing patient preferences in Alzheimer’s disease limit the usefulness of cost-
utility analysis in this particular disease. It is questionable whether the estimates of utility derived 
by EQ-5D, 15D or HUI by the disease severity states in AD accurately reflect the preferences of 
patients. The estimates seem dependent on what instrument is used; proxy-rated 15D (paper III) 
and HUI-2 seem to give higher utility scores than EQ-5D (96, 98), and who the responder is; the 
reports by the caregiver and patient differ (98). A pivotal issue is whether to consider the patients’ 
own preferences in different stages of the disease or whether to consider the preferences of the 
general public for descriptions of the same. Patients seem to have limited awareness of their own 
situation which may invalidate their own reports on their preferences. Caregivers can be used as 
proxy-raters but how do we know that their estimates accurately reflect the preferences of the 
patient? If we choose to consider the preferences of the general public, the validity of their 
estimates relies on the caregiver’s accurate description of the relevant domains of the health of 
their patient. This is a classic catch 22 dilemma as the estimates derived from caregiver reports 
cannot be validated for the same reason we did not consider the patients’ self-reported 
preferences in the first place. 
 
We may also consider the own preferences of the primary caregivers because they are also 
highly affected by the disease, and an intervention that would help the patient may have important 
benefits also to the caregivers. If those benefits can be measured in terms of an increase in 
quality of life of the caregiver, they could be included in the denominator of the cost per QALY 
gained ratio. Alternatively, we may measure the monetary value of the benefit perceived by the 
caregiver and use in a cost-benefit analysis of the intervention. In our second paper, we showed 
that such analysis could support the investment in symptomatic treatment in Alzheimer’s disease. 
4.2 Modeling 
Decision-analytic modeling has been found to be a useful tool in synthesizing the evidence base 
and informing decisions. They allow for combining inputs from multiple sources (e.g. RCTs, 
registries and observational studies), deriving from their comparative advantages, and studying 
complex scenarios which may be difficult to fully test in real life.  
 
The design of economic models in Alzheimer’s disease should be guided by the available data. 
The value of sophisticated modelling techniques is largely dependent on the data available to 
support them. This should be weighted against the transparency of the model which decreases 
with its increasing complexity. If the model is intended for informing decisions and the decision-
makers don’t understand it, they will most likely be sceptic of the results which will make the 
model useless. 
 
If and when a new endpoint is discovered which is both meaningful to patients and possible to 
measure, this should be implemented into the economic models as well. In absence of this, we 
need to consider the surrogate endpoints at hand for modeling. This may include cognition, 
function, behavior and care setting. In paper 1 we assumed a linear causality from cognition 
(representing the underlying disease), determining ADL-ability (representing the care need), 
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which would determine the care setting and finally costs of care (representing care provision). The 
true causality in AD is uncertain and the correlations between the different endpoints are probably 
more complex than suggested in paper I. Still, we believe that our simplification is a useful model 
of reality and we also showed that we could use it to replicate costs of care in our patient sample. 
More research is needed on this topic. 
 
We also found, in paper III, that function or ADL-ability is the key determinant of costs of care. 
Future models should therefore take this parameter into account in the prediction of costs of care 
over time. Cognition may not be necessary for prediction of costs or outcomes per se but it 
probably plays an important role in representing the underlying disease progression and also as 
the primary efficacy endpoint.  
 
Alzheimer’s disease leads to premature death but there is no evidence of any effect from the 
currently available treatments on mortality. For this reason, most economic models in AD have 
considered equal mortality irrespective of whether the patient gets pharmacological treatment or 
not. However, a treatment effect causing a delay in death may have perverse effects on the 
economic value of such treatment, depending on the severity of symptoms during the added 
years of life. If the life of a patient is extended while in great need of care the cost-effectiveness 
may worsen due to the reduction in mortality. The interpretation of this is not clear and needs to 
be explored further. 
 
Any economic model in AD needs to reflect the progressive course of the disease. It will not be 
sufficient to differ only between patients with and without a need for full time care, because this 
ignores important changes to the well being of the patient and their costs of care before and after 
the need for full time care is reached. Further, there may be important differences between 
individual patients that need to be considered in economic modelling; e.g. differences in 
progression rates and treatment response. If the differences are too many it may be inefficient to 
model cohorts of patients because it would be difficult to keep track of the individual differences 
between patients within the same cohort. Instead, we can simulate individual patients (micro-
simulation) each with a specific set of characteristics determining their predicted course of 
disease and response to treatment etcetera. By running many individual patient simulations we 
can estimate mean costs and outcomes of the target population. 
4.3 Assessment and valuation of informal care 
A recent review on the cost-of-illness literature in Alzheimer’s disease shows that estimates of 
informal care costs as a proportion of total costs of care varies between 8 and 78 percent (20). 
Part of this variation may be explained by differences in the studied populations, not least since 
they come from different countries with different health care systems. However, the measurement 
and valuation of informal care time varies across the studies as well, and this probably explains 
most of the variation in cost estimates. There is need for standardization in measuring the time 
spent on informal care. The RUD instrument offers one validated method for this. The valuation is 
trickier as there is no clear opportunity cost of this non-marketed good. Sensitivity analyses 
should be considered to show how robust the results are to different valuation methods. Most 
importantly, authors need to be transparent in the way data has been collected and analyzed, 
what assumptions have been made and how their results compare with previous research. 
 
Informal care may also play the key role in clinical trial. A full within-trial cost-effectiveness 
analysis may not be first priority when deciding what endpoints to measure in a pivotal registration 
trial. An alternative focus may be to accurately measure an economic endpoint of key importance 
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in the selected sample of patients. In paper IV, we showed that informal care constitutes more 
than 80 percent of the total costs of care. A treatment that would have an effect on informal care 
would therefore likely have an effect on total costs in this setting.  
4.4 Limitations 
The selection of patients into a study needs to be considered when interpreting the results. The 
study findings cannot be generalized to a different population than that from which the study 
subjects have been recruited. Recruiting subjects from a general population is preferred in 
epidemiologic studies because the results may then be inferred to that population. Depending on 
the objective of the study, the target population may be narrowed down, not to be representative 
to the whole population but instead to patients with a certain disease or treated with a certain drug 
etcetera. The SATS study (paper I) aimed to observe patients treated with cholinesterase 
inhibitors in a routine clinical setting. Because they were recruited from memory clinics they may 
not be valid for patients cared for in primary care settings. The sample selected for the cost study 
(paper III) was recruited from a mix of primary and secondary care centers and also recruited 
patients both living in the community and in residential care settings. The results from this study 
should therefore be more representative to the AD population in the countries studied. There may 
also be practical reasons to have more strict selection criteria for a study. In clinical trials the 
inclusion and exclusion criteria are commonly set to accommodate the measurement of efficacy 
e.g. by excluding patients without a knowledgeable informant that can accurately report 
outcomes, or patients with fatal co-morbidity potentially causing drop-out. The fourth paper was 
based on such a clinical trial and the findings are therefore not applicable to the general AD 
population.  
 
Attrition is a common and inevitable problem of any longitudinal study. In experimental trials drop-
outs are commonly caused by side-effects of the study drug or perceived lack of efficacy which 
may lead to the study subject withdrawing their consent to participate. Also in non-experimental 
studies, subjects drop out due to e.g. changes in their living situation or death. Sensitivity analysis 
should be performed at least comparing the baseline characteristics of subjects that have 
dropped out and those that have completed the study. The implications of the attrition in the 
SATS study (paper I) and the clinical trial analysis (paper IV) were discussed in each respective 
paper but not considered to have any significant impact on the study findings. 
 
The cost of a patient with AD is not the same as their cost due to this disease. Part of the overall 
health care consumption of a patient may be caused by other morbidities. To assess the costs 
due to a disease we may ask a person what health care resources were used specifically due to 
that disease, or even better compare the costs of a sample of patients with the disease with a 
similar sample of subjects without the disease. In our cost study (paper III), we were interested in 
the cost differences between patients with different severities of AD, and we estimated a model to 
predict the additional costs of an increase in severity according to the key domains. 
 
A similar issue affects the assessment of instrumental ADLs in elderly men. We are generally 
interested in the impact of Alzheimer’s disease on the patients’ ability to perform ADLs but in 
many cases they have never carried out certain ADLs (e.g. shopping, cleaning or washing) 
because their wife has taken care of this for them. In these instances, the instrumental ADL 
domains are not applicable because their dependence may not be due to their disease but 
instead caused by traditional family structures. The results of the SATS study (paper I) are 
therefore strictly not applicable to patients that have never carried of certain instrumental ADLs.  
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The statistical model estimated to predict disease progression in the SATS study was limited by 
the data available. Behaviour is an important determinant of costs of care in Alzheimer’s disease 
but was not assessed within the SATS study. Further, the hypothesized link between cognition 
and ADL-ability is probably a simplification of reality. A longitudinal study assessing cognition, 
ADL-ability and behaviour over time as well as key economic endpoints is needed to explore the 
co-variance between the disease severity outcomes and their impact on economic outcomes over 
time. 
 
There are a number of limitations to note with regard to assessing costs. First, the assessment of 
resource utilization in the SATS study (paper I) lacks important resources including informal and 
outpatient care. The other two studies assessing costs (paper III and IV) includes the RUD Lite 
instrument which should capture 95 percent of the total costs of care (87). Second, relatively large 
samples are required to estimate the mean cost of inpatient care because hospitalizations are 
infrequent but very costly once they occur which results in influential outliers where samples are 
too small. The studies included in this thesis are all too small to provide robust estimates of 
inpatient care costs. Third, the informal care costs are sensitive to both the methods for 
measuring care time and the subsequent valuation of the same.  
 
The estimates of caregivers’ willingness-to-pay for reductions in care need (paper II) have two 
important limitations. First, previous studies have shown a discrepancy between stated and actual 
willingness-to-pay, as respondents may say that they would accept an offer in a hypothetical 
scenario but change their minds once they got the opportunity in real life. We tried to control for 
this by only considering certain responses as accepts in the calculations. This method has been 
validated in previous research (54). Second, we expect that caregivers’ perceived value of a 
reduction in care need is dependent of the cause of this reduction. We chose to state that the 
reduction in care need was caused by an improvement in the health of the patient, because we 
did not want to introduce any noise in the estimation related to uncertainty of the cause of the 
reduction in care need. How this affected the results is unknown and may be subject for further 
studies. 
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4.5 Future research 
The natural course of Alzheimer’s disease presents many challenges for the economic evaluation 
of AD treatment. These challenges may be overcome by more research into the field. The 
following are suggested needs for further research. 
 
 The lack of biomarkers inhibits accurate diagnosis and staging of disease severity. 
Instead, surrogate endpoints are used to describe the severity of symptoms and they may 
be of little relevance to patients and have limited correlation with costs. More research is 
therefore needed on the identification of biomarkers and endpoints that are relevant to 
patients. 
 The progressive nature of the disease prevents the use of traditional state transition 
models to describe the course of the disease, and multifaceted and inter-related 
symptoms further complicate an accurate description of the disease process. There are 
methods available to improve the economic models for evaluation of AD treatment, but the 
relevant applications need to be developed and there is need for further data to support 
them. 
 The cognitive impairment of patients restricts their ability to complete self-reported 
outcomes and inform decision-makers on their preferences for different outcomes. There 
is need both for methods to accurately elicit patient preferences and alternative methods 
to determine the value of treatment in absence of valid patient-reported outcomes. 
4.6 Health policy implications 
Economic evaluation will be an important tool for decisions on the allocation of health care 
resources also in the future. The alternative, to neglect aspects of costs in decision-making, is 
simply not feasible because it will lead to suboptimal allocation of scarce health care resources. 
Economists may prefer cost-benefit analysis, i.e. the translation of all consequences from a given 
health care intervention into monetary values, because it enables direct comparison of costs and 
consequences. The decision rule that follows is simply to invest in all strategies with a positive net 
benefit (i.e. the monetary value of the benefits is larger than the costs). However, the monetary 
value of the consequences of a health care intervention can be difficult to assess, which limits the 
usefulness of cost-benefit analysis in practise. 
 
NICE and TLV, among other key stakeholders in health care decision making, prefer cost-utility 
analysis because it enables the comparison of interventions across disease areas. By selecting 
interventions with the lowest cost per QALY gained until their budget is exhausted, decision-
makers may optimize the allocation of the resources allotted to them. However, neither NICE nor 
TLV has a fixed budget to work from and cost-utility analysis does not provide any guidance on 
when to stop adding interventions with higher costs per added QALY. Still, they need to consider 
some threshold for what additional cost per added QALY they are willing to accept. Even in 
systems where the budget actually is fixed, how would policy makers know what the optimal size 
of the health care budget should be? 
 
So what determines the threshold or size of health care budget in practise? The key to this 
discussion is that the benefits of any health care intervention indeed will be valued against its 
opportunity costs, be that other health care interventions, other investments by public funds, or 
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even lower taxes and insurance premiums. In many instances this valuation is made implicitly, 
without rigid analysis, as part of an overall policy, guided by public opinion or simply based on 
how things were done previously. Alternatively, the economic evaluation can be done explicitly by 
studying public preferences for different scenarios and thereby inform decisions that lead to 
optimal allocation of resources. This will likely be a key issue for future health policy. 
 
Another key issue is how to handle the uncertainty of the outcomes of an investment into a new 
drug treatment. Traditionally, the drug developer bares the full cost of this uncertainty up until 
market launch where after the cost is shared with the payer. That is, the payer agrees to pay a 
certain price for the drug according to its expected outcomes. If the drug doesn’t meet these 
expectations, the developer may lose from a low market penetration, or if the drug is widely used 
despite poor outcomes, the payer loses from the poor outcomes in relation to the agreed price. In 
practise, the actual outcomes of a new treatment may be difficult to monitor if post-marketing 
studies are not set up for this purpose. A recent development is for payers and drug developers to 
enter risk-sharing agreements in which the drug developer gets paid for performance based on 
post-marketing studies where the actual outcomes are assessed in the real life setting (102). This 
may be an efficient way of taking control over the cost of uncertainty in health care decision 
making. 
 
Another important role of economic evaluation is to visualize cost offsets within different parts of 
the health care system. Some countries have a societal perspective in their decision-making 
process which increases the chance of making decisions that are beneficial to the society as a 
whole. Health care systems in other countries suffer from silo-effects where important 
investments risk not to get funding because the benefits and costs affect different sectors, each 
with their own independent budgets. In such systems there is a need to find ways to transfer 
benefits from one sector to another. 
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5. Conclusions 
 
 Cognitive decline, gradual loss of ADL-ability and emergence of behavioural symptoms all 
play a key role in the development of care needs of AD patients. ADL-ability has the 
strongest correlation with costs of care. 
 Caregivers have a substantial willingness to pay for a treatment that reduces patient care 
need. Mean willingness-to-pay was estimated at between £59 and £144, depending on 
country, per month for a reduction of one hour per day. 
 The care provided by informal caregivers constitutes a substantial part of the total care for 
patients typically enrolled in clinical trials to assess the efficacy of a drug in mild to 
moderate AD. 
 Health utility estimates of AD patients are highly dependent on the selected methodology 
including choice of instrument, respondent and utility tariffs.  
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